Compare NRT & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | FBIO |
|---|---|---|
| Founded | 1975 | 2006 |
| Country | United States | United States |
| Employees | N/A | 101 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 83.7M |
| IPO Year | 1995 | N/A |
| Metric | NRT | FBIO |
|---|---|---|
| Price | $9.29 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 106.7K | ★ 430.6K |
| Earning Date | 03-02-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | $44.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.01 | $1.33 |
| 52 Week High | $10.49 | $4.53 |
| Indicator | NRT | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 27.96 |
| Support Level | $8.51 | $1.76 |
| Resistance Level | $9.66 | $2.71 |
| Average True Range (ATR) | 0.51 | 0.19 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 48.44 | 9.09 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.